Monitoring of immunologic therapies

Manual of Molecular and Clinical Laboratory Immunology: 7th edition

Volumn , Issue , 2022, Pages 1171-1182

  Whiteside, Theresa L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Biologic therapies; Cytokines; Immunotoxins; Monoclonal antibodies (MAbs); Mononuclear cells (MNC)

Indexed keywords

EID: 38649138859     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1128/9781555815905.ch133     Document Type: Chapter

References (26)

1. Aebersold, P. M., C. Hyatt, S. Johnson, K. Hines, L. Korcak, M. Sanders, M. Lotze, S. Topalian, J. Yang, and S. A. Rosenberg. 1991. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J. Natl. Cancer Inst. 83:932-937.
2. Allegretta, M., M. B. Atkins, R. A. Dempsey, E. C. Bradley, M. W. Konrad, A. Childs, S. N. Wolfe, and J. W. Mier. 1986. The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2). J. Clin. Immunol. 6:481-490.
3. Altman, J. D., P. A. H. Moss, P. R. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94-96.
4. Asai, T., W. J. Storkus, and T. L. Whiteside. 2000. Evaluation of the modified ELISPOT assay for interferon-γ production in monitoring of cancer patients receiving antitumor vaccines. Clin. Diagn. Lab. Immunol. 7:145-154.
5. Caligiuri, M. A., C. Murray, and M. J. Robertson. 1993. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J. Clin. Investig. 91:123-132.
6. Elder, E. M., and T. L. Whiteside. 1992. Processing of tumors for vaccine and/or tumor-infiltrating lymphocytes, p. 817-819. In H. Friedman, N. R. Rose, E. C. deMacario, J. L. Fahey, H. Friedman, and G. M. Penn (ed.), Manual of Clinical Laboratory Immunology, 4th ed. American Society for Microbiology, Washington, D.C.
7. Elder, M. B., D. Lin, J. Clever, A. C. Chan, T. J. Hope, A. Weiss, and T. G. Parslow. 1994. Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase. Science 264:1596-1599.
8. Foon, K. A., W. J. John, M. Chakraborty, R. Das, A. Teitelbaum, J. Garrison, O. Kashala, S. K. Chatterjee, and M. Bhattacharya-Chatterjee. 1999. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J. Clin. Oncol. 17:2889-2895.
9. Friedman, H. 2004. Personal communication.
10. Gambacorti-Passerini, C., J. A. Hank, M. R. Albertini, A. A. Borchert, K. H. Moore, J. H. Schiller, R. Bechhofer, E. C. Borden, B. Storer, and P. M. Sondel. 1993. A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer. J. Immunother. 13:43-48.
11. Givan, A. L., J. L. Fisher, M. Waugh, M. S. Ernstoff, and P. K. Wallace. 1999. A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. J. Immunol. Methods 230:99-112.
12. Hank, J. A., P. C. Kohler, G. Weil-Hillman, N. Rosenthal, K. H. Moore, B. Storer, D. Minkoff, J. Bradshaw, R. Bechhofer, and P M. Sondel. 1988. In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin-2. Cancer Res. 48:1965-1971.
13. Hank, J. A., J. A. Sosman, P. C. Kohler, R. Bechhofer, B. Storer, and P. M. Sondel. 1990. Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2. J. Biol. Response Mod. 9:5-19.
14. Herberman, R. B. 1985. Design of clinical trials with biological response modifiers. Cancer Treat. Rep. 69:1161-1164.
15. Ko, B. K., K. Kawano, J. L. Murray, M. L. Disis, C. L. Efferson, H. M. Kuerer, G. E. Peoples, and C. G. Ioannides. 2003. Clinical studies of vaccines targeting breast cancer. Clin. Cancer Res. 9:3222-3234.
16. Kuss, I., B. Hathaway, R. L. Ferris, W. Gooding, and T. L. Whiteside. 2004. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 10:3755-3762.
17. Reichert, T. E., C. Scheuer, R. Day, W. Wagner, and T. L. Whiteside. 2001. The number of intratumoral dendritic cells and x chain expression in T cells as prognostic and survival biomarkers in human oral carcinomas. Cancer 91:2136-2147.
18. Rosenberg, S. A., M. T. Lotze, J. C. Yang, P. M. Aebersold, W. M. Linehan, C. A. Seipp, and D. E. White. 1989. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 210:474-485.
19. Shevach, E. M. 2004. Fatal attraction: tumors beckon regulatory T cells. Nat. Med. 9:900-901.
20. Sondel, P. M., P. C. Kohler, J. A. Hank, K. H. Moore, N. S. Rosenthal, J. A. Sosman, R. Bechhofer, and B. Storer. 1988. Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. Cancer Res. 48:2561-2567.
21. Van Parijs, L., and A. K. Abbas. 1998. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280:243-248.
22. Whiteside, T. L. 2000. Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy. Clin. Diagn. Lab. Immunol. 7:327-332.
23. Whiteside, T. L. 2002. Apoptosis of immune cells in the tumor microenvironment and peripheral circulation of patients with cancer: implications for immunotherapy. Vaccine 20:A46-A51.
24. Whiteside, T. L. 2002. Cytokine assays. Biotechniques 33:4-15.
25. Whiteside, T. L. 2004. Down-regulation of Z chain expression in T cells: a biomarker of prognosis of cancer? Cancer Immunol. Immunother. 53:865-876.
26. Whiteside, T. L., J. Stanson, M. R. Shurin, and S. Ferrone. 2004. Antigen processing machinery (APM) in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. J. Immunol. 173: 1526-1534.